- Absorption and Half-Life
-
Holford N
- KMID: 2413836
- Transl Clin Pharmacol.
- 2016 Dec;24(4):157-160.
- doi: 10.12793/tcp.2016.24.4.157
This tutorial deals with basic concepts of absorption processes and links previous tutorials on clearance and volume of distribution to introduce the concept of half-life. The time course of both... -
- CITED
-
- Close
- SHARE
-
- Close
- Pitfalls in the calculation of hemodialysis clearance and in the assessment of dialysis efficacy
-
Atkinson A
- KMID: 2413835
- Transl Clin Pharmacol.
- 2016 Dec;24(4):153-156.
- doi: 10.12793/tcp.2016.24.4.153
The therapeutic technique of hemodialysis and the concept of clearance have both followed a long but instructive course of development. In addition, it recently has been shown that physiological changes... -
- CITED
-
- Close
- SHARE
-
- Close
- R-based reproduction of the estimation process hidden behind NONMEM® Part 2: First-order conditional estimation
-
Bae KS, Yim DS
- KMID: 2413837
- Transl Clin Pharmacol.
- 2016 Dec;24(4):161-168.
- doi: 10.12793/tcp.2016.24.4.161
The first-order conditional estimation (FOCE) method is more complex than the first-order (FO) approximation method because it estimates the empirical Bayes estimate (EBE) for each iteration. By contrast, it is... -
- CITED
-
- Close
- SHARE
-
- Close
- An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials
-
Chae D, Park K
- KMID: 2413841
- Transl Clin Pharmacol.
- 2016 Dec;24(4):189-193.
- doi: 10.12793/tcp.2016.24.4.189
In oncology trials, patients are withdrawn from study at the time when progressive disease (PD) is diagnosed, which is defined as 20% increase of tumor size from the minimum. Such... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of JOINS® on the pharmacokinetic profiles of aceclofenac in healthy Korean volunteers: an open-label, multiple-dose, one sequence, two-period study
-
Kim D, Oh ES, Kim CO, Choi C, Chang MJ, Park MS
- KMID: 2413838
- Transl Clin Pharmacol.
- 2016 Dec;24(4):169-174.
- doi: 10.12793/tcp.2016.24.4.169
JOINS, an herbal anti-arthritic drug, was developed for the treatment and pain relief of knee osteoarthritis. It was approved for use in Korea by the Ministry of Food and Drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetics and safety profiles of tadalafil/tamsulosin HCl fixed-dose combination capsule under fasted and fed condition in healthy volunteers
-
Jin BH, Yoo BW, Oh ES, Yang S, Jung J, Park MS
- KMID: 2413839
- Transl Clin Pharmacol.
- 2016 Dec;24(4):175-182.
- doi: 10.12793/tcp.2016.24.4.175
Co-administration of tadalafil and tamsulosin HCl in patients with benign prostate hyperplasia and erectile dysfunction is increasing in clinical settings. Development of fixed-dose combination (FDC) of tadalafil and tamsulosin HCl... -
- CITED
-
- Close
- SHARE
-
- Close
- Screening study for genetic polymorphisms affecting pharmacokinetics of pioglitazone
-
Yun JY, Kim BH, Lee JH, Lee K, Kwack K, Yim SV
- KMID: 2413842
- Transl Clin Pharmacol.
- 2016 Dec;24(4):194-202.
- doi: 10.12793/tcp.2016.24.4.194
Pioglitazone is known to have antidiabetic effects through decreasing peripheral, hepatic and vascular insulin resistance by the stimulation of PPAR gamma. To address the possible genetic factors affecting the pharmacokinetics... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetic characteristics of cilostazol 200 mg controlled-release tablet compared with two cilostazol 100 mg immediate-release tablets (Pletal) after single oral dose in healthy Korean male volunteers
-
Son JD, Cho SM, Choi YW, Kim SH, Kwon IS, Jin EH, Kim JW, Hong JH
- KMID: 2413840
- Transl Clin Pharmacol.
- 2016 Dec;24(4):183-188.
- doi: 10.12793/tcp.2016.24.4.183
Cilostazol controlled-release (CR) tablets have recently been developed by Korea United Pharm (Seoul, Korea). The tablets use a patented double CR system, which improves drug compliance by allowing "once daily"... -
- CITED
-
- Close
- SHARE
-
- Close
